ArticleEuropean journal of pediatrics2026
Kaposiform vascular tumors with Kasabach-Merritt phenomenon: a case series of KHE and KLA from a tertiary care center in India.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kasabach-Merritt phenomenon (KMP) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and profound hypofibrinogenemia and it denotes the presence of underlying Kaposiform hemangioendothelioma (KHE)/Tufted angioma (TA). Kaposiform lymphangiomatosis is associated with moderate thrombocytopenia and hypofibrinogenemia and usually presents with hemorrhagic pleural and pericardial effusion. Medical management with a combination of drugs such as steroids, vincristine, propranolol, and sirolimus along with cryoprecipitate transfusion and restricted platelet transfusion is the cornerstone of management in most cases. As angiogenesis is due to the vascular endothelial growth factor (VEGF), especially VEGFA/VEGFR1, anti-VEGF inhibitors can be tried in Kaposiform hemangioendothelioma in refractory cases. We analyzed five children who presented with features of Kasabach-Merritt phenomenon and one child with "KMP like", who on further evaluation was found to have underlying vascular tumors. The most common treatment regimen was steroids with vincristine and the addition of sirolimus. One refractory case required bevacizumab and one child who had a central-conducting abnormality with pleural effusion with diffuse splenic involvement required splenectomy.
conclusionA child with microangiopathic hemolytic anemia with consumptive coagulopathy should be evaluated for underlying Kaposiform hemangioendothelioma and in the presence of pleural and pericardial effusion with "KMP-like" features there could be underlying Kaposiform lymphangiomatosis (KLA) and should be treated promptly with medical management and supportive care. WHAT IS KNOWN: • A child with microangiopathic hemolytic anemia with consumptive coagulopathy and thrombocytopenia think of Kasaback Merritt Phenomenon. WHAT IS NEW: • Child who presents with hemorrhagic pleural eff usion and associated with central conducting lymphatic anomalies think of Kaposiform lymphangiomatosis(KLA).
Indexed as
Identifiers
42033477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.